Search Results
Your search for ,maY matches 16485 pages
Showing 5001 - 5050Study Explores Rates of Germline Mutations in Patients With Colorectal Cancer
In a recent study published by Uson Junior et al in Clinical Gastroenterology and Hepatology, researchers found one in six patients with colorectal cancer had an inherited cancer-related genetic mutation, which may be linked to a predisposition to the disease. In addition, the researchers...
National Survey Finds Average-Risk Individuals Prefer Stool-Based Tests Over Colonoscopy for Colorectal Cancer Screening
A national survey conducted by Zhu et al to identify patient preferences among colorectal cancer screening modalities to improve population adherence to colorectal cancer screening has found, when presented with a choice, most individuals with an average risk of colorectal cancer prefer stool-based ...
MANIFEST-2: CPI-0610 Shows Benefit in Myelofibrosis
The novel targeted agent CPI-0610 enhanced responses to ruxolitinib in patients with myelofibrosis enrolled in the global phase II MANIFEST-2 trial, investigators reported at the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition.1,2 “Preliminary data demonstrate the...
Genitourinary Oncology Highlights 2020–2021 Almanac
Landmark changes in the treatment of genitourinary cancers have occurred over the past year, as summarized in this year’s Genitourinary Oncology Almanac from The ASCO Post. Starting with our area of focus, metastatic renal cell carcinoma, the saga continues with two more positive phase III trials...
Immune Checkpoint Inhibitors and Cutaneous Toxicity: Population-Level Analysis
Immune checkpoint inhibitors have transformed treatment for many advanced cancers, but short-term clinical trials and small observational studies have linked the medications with various side effects, most commonly involving the skin. A more comprehensive, population-level analysis now provides a...
To Advance Health Equity, Put Real-World Cancer Data to Work
Despite decades of scientific progress against cancer, access to treatment remains highly unequal. Some of the reasons—like institutional racism and poverty—are a reflection of our broader society. Other inequities may go unrecognized but are no less damaging. People with underlying health...
FDA Pipeline: Recent Designations in Urothelial Cancer, Cervical Cancer, Cholangiocarcinoma, and More
Recently, the U.S. Food and Drug Administration (FDA) issued regulatory decisions related to treatments for urothelial cancer, cervical cancer, cholangiocarcinoma, solid tumors, and colorectal cancer. Acceptance of Two Supplemental Biologics License Applications for Enfortumab Vedotin-ejfv in...
Expert Point of View: Deborah Armstrong, MD
The invited discussant of the SOLO-1 trial, Deborah Armstrong, MD, Professor of Oncology and Director of the Breast and Ovarian Surveillance Service at Johns Hopkins Medicine, said the update provides “important information for us,” showing that 2 years of maintenance olaparib conveys “a really...
Pediatric Adrenocortical Carcinoma: Different Treatment Strategies by Disease Stage
As reported in the Journal of Clinical Oncology by Carlos Rodriguez-Galindo, MD, and colleagues, the Children’s Oncology Group ARAR0332 Protocol has identified outcomes associated with different treatment strategies according to disease stage in patients with pediatric adrenocortical carcinoma....
Addition of Avelumab to Chemoradiotherapy in Previously Untreated Patients With Locally Advanced Head and Neck Cancer
As reported in The Lancet Oncology by Nancy Y. Lee, MD, and colleagues, the phase III JAVELIN Head and Neck 100 trial showed no improvement in progression-free survival with the addition of the PD-L1 inhibitor avelumab to chemoradiotherapy in patients with previously untreated locally advanced...
Overweight Breast Cancer Survivors May Be at Increased Risk of Developing a Secondary Malignancy
Breast cancer survivors who are overweight have a statistically significant increased risk of developing second primary cancers, according to results from a study conducted by Feigelson et al and published in the Journal of the National Cancer Institute. “These findings have important public health ...
Recent Studies Explore Efficacy of COVID-19 Vaccination in Patients With Leukemia and Myeloma
Two new studies published in the journal Blood suggest that the BNT162b2 mRNA COVID-19 vaccine may have reduced efficacy in individuals with chronic lymphocytic leukemia (CLL) and multiple myeloma. According to researchers, these studies could help inform the ideal time for vaccination of these...
Georgina V. Long, MD, PhD, on Melanoma: Nivolumab Plus Ipilimumab vs Nivolumab Alone
Georgina V. Long, MD, PhD, of the Melanoma Institute Australia, University of Sydney, discusses results of the CheckMate 915 trial, which may reinforce nivolumab as an adjuvant standard of care in patients with stage IIIB–D/IV melanoma, with or without complete lymphadenectomy (Abstract CT004).
Matthew G. Vander Heiden, MD, PhD, and Karen H. Vousden, PhD: A Conversation About the Role of Diet in Cancer
Karen H. Vousden, PhD, of The Francis Crick Institute, and Matthew G. Vander Heiden, MD, PhD, of the Koch Institute for Integrative Cancer Research at MIT, discuss emerging evidence that diet may affect which nutrients are available to tumor cells, which can influence both tumor growth and response ...
Adult Survivors of AYA Cancers May Be More Likely to Experience Medical Financial Hardship
A new study has found higher rates of medical financial hardship among adult survivors of adolescent and young adult (AYA) cancers than in adults without a history of cancer in the United States. The research was published by Lu et al in JNCI: The Journal of the National Cancer Institute....
Ralph R. Weichselbaum, MD, on Oligometastasis: Biologic Basis and Therapeutic Opportunities
Ralph R. Weichselbaum, MD, of the University of Chicago, discusses oligometastasis as a part of the metastatic spectrum where ablative therapies, such as surgery or stereotactic body radiotherapy, may be curative alone or with systemic agents, as well as some potential biomarkers to guide treatment ...
Charlotte E. Ariyan, MD, PhD, on Metastasectomy After Immunotherapy: Is It Effective?
Charlotte E. Ariyan, MD, PhD, of Memorial Sloan Kettering Cancer Center, discusses improved outcomes with metastasectomy in the setting of checkpoint inhibitors, with the removal of residual disease and “escape” lesions. Surgical outcomes may also be better than targeted treatments, although...
Jeanne Tie, MD, MBChB, on Circulating Tumor DNA, Minimal Residual Disease, and Adjuvant Treatment
Jeanne Tie, MD, MBChB, of the Peter MacCallum Cancer Centre, discusses how to improve the current, somewhat imprecise, approach based on pathologic staging alone, used to select patients for adjuvant treatment. Circulating tumor DNA analysis after curative-intent treatment may detect minimal...
Joann G. Elmore, MD, MPH, on Cancer Diagnosis: When Pathologists Disagree, Artificial Intelligence May Help
Joann G. Elmore, MD, MPH, of the UCLA Fielding School of Public Health, discusses previous studies that show wide variability in cancer diagnoses, the uncertainties introduced by computer-aided detection tools, and new research on artificial intelligence and machine learning that may lead to more...
Certain Genetic Mutations May Increase Risk of Death From Infection in Patients With CLL
Death from infection—the leading cause of death for patients with chronic lymphocytic leukemia (CLL)—may be linked to specific gene mutations, according to results from a study published by Else et al in the journal Leukemia. Testing for these mutations could be used to identify patients at a...
Squamous Cell Carcinoma of the Head and Neck: Current Status and Future Directions
Although head and neck cancers include multiple histologies and primary sites, squamous cell carcinomas (SCC) originating in the oropharynx, oral cavity, larynx, or hypopharynx are the most common. Today, we recognize different types of head and neck cancers, primarily those that are human...
Linda T. Vahdat, MD, MBA, on Triple-Negative Breast Cancer: Targeting the Tumor Microenvironment
Linda T. Vahdat, MD, MBA, of Memorial Sloan Kettering Cancer Center, discusses results of a phase II trial designed to test the concept that targeting the tumor microenvironment by depleting copper may prevent metastases, essentially disrupting the infrastructure that contributes to tumor spread.
Carey K. Anders, MD, on Brain Metastases: Integrating Immunotherapy Into Clinical Care
Carey K. Anders, MD, of the Duke Cancer Center, discusses the ways in which treatment of brain metastases arising from solid tumors has moved into a new era of patient care and how the field may advance.
Patrizia Cavazzoni, MD, Named Director of the FDA’s Center for Drug Evaluation and Research
On April 12, Patrizia Cavazzoni, MD, was announced as the Director of the Center for Drug Evaluation and Research (CDER) at the U.S. Food and Drug Administration (FDA). Janet Woodcock, MD, Acting Commissioner of the FDA, noted on Twitter: “Pleased to announce the permanent appointment of Patrizia ...
Adjuvant Nivolumab for Resected Esophageal or Gastroesophageal Junction Cancer After Neoadjuvant Chemoradiotherapy: CheckMate 577
As reported in The New England Journal of Medicine by Ronan J. Kelly, MBBCh, MBA, and colleagues, an interim analysis of the phase III CheckMate 577 trial has shown a significant improvement in disease-free survival with adjuvant nivolumab vs placebo in patients with resected esophageal or...
Cancer Aneuploidy May Predict Response to Immunotherapy in Patients With NSCLC
Lower levels of cancer aneuploidy were associated with more favorable outcomes after immune checkpoint inhibition in patients with non–small cell lung cancer (NSCLC), according to data presented by Alessi et al at the virtual American Association for Cancer Research (AACR) Annual Meeting 2021...
Tumor Mutational Burden as Predictor of Immune Response: Variance Between Female and Male Patients With Melanoma
Tumor mutational burden (TMB) was an accurate predictor of response to treatment with immune checkpoint inhibitors for female patients with melanoma, but not for male patients, according to results of a study presented by Sinha et al during the virtual American Association for Cancer Research...
Expert Point of View: Jacqueline S. Garcia, MD
Jacqueline S. Garcia, MD, of Dana-Farber Cancer Institute, who was not involved in this study, agreed that “novel therapies for relapsed/refractory AML that are biomarker-directed are a dire unmet need and may help patients avoid ineffective therapies and unnecessary toxicity.” She noted that 36%...
RARA Agonist Plus Azacitidine Shows Encouraging Activity in Relapsed/Refractory AML
The novel agentSY-1425 combined with azacitidine appears to be active in retinoic acid receptor alpha (RARA) superenhancer–positive newly diagnosed and relapsed or refractory acute myeloid leukemia (AML), according to the results of a phase II trial presented at the 2020 American Society of...
FDA Grants Accelerated Approval to Sacituzumab Govitecan-hziy for Advanced Urothelial Cancer
On April 13, 2021, the U.S. Food and Drug Administration (FDA) granted accelerated approval to sacituzumab govitecan-hziy (Trodelvy) for patients with locally advanced or metastatic urothelial cancer who previously received a platinum-containing chemotherapy and either a PD-1 or PD-L1 inhibitor....
Liquid Biopsy Plus MRI for Predicting Response to Neoadjuvant Chemotherapy in Patients With Breast Cancer
Cirmena et al discussed whether using a liquid biopsy test to assess plasma cell-free DNA (cfDNA) integrity could improve the accuracy of magnetic resonance imaging (MRI) for predicting the achievement of complete response among patients with locally advanced breast cancer who had received...
Patients With Ovarian Cancer Face an Increased Risk of Mental Illness
Women diagnosed with ovarian cancer were more than three times more likely than the general public to be diagnosed with anxiety, depression, and adjustment disorder, according to results presented by Hu et al during the virtual American Association for Cancer Research (AACR) Annual Meeting 2021...
Patients of Different Races With Early-Onset Colorectal Cancer Exhibit Distinct Genetic Features
Racial differences in genetic mutations were observed among patients with early-onset colorectal cancer, according to data presented by Andreana N. Holowatyj, PhD, MS, during the virtual American Association for Cancer Research (AACR) Annual Meeting 2021 (Abstract 101). The incidence of early-onset ...
American Cancer Society Names Karen E. Knudsen, MBA, PhD, as Its Next Chief Executive Officer
Karen E. Knudsen, MBA, PhD, will be the next Chief Executive Officer of the American Cancer Society and its advocacy affiliate, the American Cancer Society Cancer Action Network (ACS CAN), starting June 1, 2021. She will take the reins from the retiring Gary Reedy, who has served as both...
Expert Point of View: David A. Braun, MD, PhD
Invited discussant David A. Braun, MD, PhD, of Dana-Farber Cancer Institute, Boston, said there are a couple of established pillars of systemic therapy for metastatic renal cell carcinoma (RCC). “An immune checkpoint inhibitor is a strong pillar, a [vascular endothelial growth factor tyrosine...
Belzutifan Shows Activity in Advanced Renal Cell Carcinoma, Both as a Single Agent and in Combination Therapy
Separate studies presented at the 2021 Genitourinary Cancers Symposium provide supportive evidence for belzutifan (formerly MK-6482) as an active treatment for metastatic clear cell renal cell carcinoma (RCC). One study showed single-agent activity for this novel approach in an early-phase trial,...
Cleveland Clinic Appoints Brian Bolwell, MD, FACP, to New Leadership Role; Jame Abraham, MD, to Serve as Acting Chair, Taussig Cancer Institute
Brian Bolwell, MD, FACP, has been appointed to the newly created role of Chair, Physician Leadership and Development within the Mandel Global Leadership and Learning Institute at Cleveland Clinic. His new position is effective May 1, 2021. Dr. Bolwell has served as Chair of Cleveland Clinic...
Unselected Autologous Tumor-Infiltrating Lymphocyte Therapy for Metastatic Cutaneous Melanoma
Treatment with unselected autologous tumor-infiltrating lymphocytes (TILs) showed early clinical efficacy among patients with advanced melanoma, according to results presented by Hawkins et al during week 1 of the virtual American Association for Cancer Research (AACR) Annual Meeting 2021 (Abstract ...
Early-Phase Study Explores CAR T-Cell Therapy for Relapsed or Refractory B-Cell Lymphoma
Bispecific anti-CD19/CD20 chimeric antigen receptor (CAR) T-cell therapy was well tolerated and showed signs of clinical efficacy in patients with relapsed/refractory B-cell lymphoma, according to phase I clinical trial data presented by Ghafouri et al during week 1 of the virtual American...
Cancer and COVID-19: Reflections at 1 Year
We who live and work in Seattle recently took note of two milestones: the first death of a patient from COVID-19 reported in the United States in Seattle on February 28, 2020, and recognition of 5,000 deaths from COVID-19 in the state of Washington on March 2, 2021. The juxtaposition of these two...
Novel Insights in Myelodysplastic Syndromes: Highlights From 2020 ASH Meeting
To complement The ASCO Post’s comprehensive coverage of the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition, here are several abstracts selected from the meeting proceedings focusing on novel clinical trial findings in myelodysplastic syndromes (MDS). For full details of...
Expert Point of View: Gillianne G.Y. Lai, MBBS
Gillianne G.Y. Lai, MBBS, of the National Cancer Centre, Singapore, discussed the presentations on novel agents for exon 20 insertion mutations in non–small cell lung cancer (NSCLC), which account for about one-third of tyrosine kinase resistance mutations. Although tyrosine kinase mutations are...
Cardiovascular Concerns With the Use of VEGFR Tyrosine Kinase Inhibitors
Tyrosine kinase inhibitors targeting the vascular endothelial growth factor receptor (VEGFR) have proved to be effective drugs in the treatment of many solid tumors. However, their clinical benefit may come at the cost of cardiovascular toxicity if clinicians are not vigilant and proactive. During...
Expert Point of View: Richard K. Valicenti, MD, FASTRO
“The absolute risk reduction in metastasis ranges from 2% to 12% by 10 years. Given this heterogeneity, there is a strong rationale for better prognostic markers to personalize treatment of prostate cancer. Nearly all men treated with androgen-deprivation therapy have variable side effects that...
Novel Decision-Making Tool for Androgen-Deprivation Therapy for Patients With Prostate Cancer
According to a retrospective study, the combined clinical and cell-cycle risk (CCR) score may be able to accurately predict which patients with intermediate- and high-risk prostate cancer will have little additional benefit from androgen-deprivation therapy added to dose-escalated radiotherapy and...
Dana-Farber Oncologist Benjamin Ebert, MD, PhD, Awarded Sjöberg Prize for Cancer Research
Benjamin Ebert, MD, PhD, Chair of Medical Oncology at Dana-Farber Cancer Institute, George P. Canellos, MD, and Jean S. Canellos Professor of Medicine at Harvard Medical School, and Institute Member of Broad Institute of Harvard and MIT, has been awarded the Sjöberg Prize, an annual international...
Expert Point of View: Xin Gao, MD
Xin Gao, MD, a medical oncologist at Mass General Hospital and Instructor at Harvard Medical School, said these were important findings. “Analyses of patient-reported outcomes pertaining to health-related quality-of-life measures from CheckMate 9ER showed significantly improved quality-of-life...
Expert Point of View: Ursula Matulonis, MD
Invited discussant, Ursula Matulonis, MD, Chief of the Division of Gynecologic Oncology at Dana-Farber Cancer Institute, Boston, applauded the improved outcomes favoring lenvatinib/pembrolizumab in the confirmatory KEYNOTE-775 trial. “This represents the start of a new era in endometrial cancer...
Yoga in Oncologic Care: An Evidence-Based Treatment to Improve Outcomes
The ASCO Post’s Integrative Oncology series is intended to facilitate the availability of evidence-based information on integrative and complementary therapies sometimes used by patients with cancer. Increasingly, patients with cancer desire nonpharmacologic strategies for managing their...
I’m Living the Life I Was Destined to Have
At 33, I’m not living the life I had imagined for myself. If cancer hadn’t interrupted my plans, I would be serving in the United States Army Special Forces by now, a profession that was inspired by my father’s career as a military officer and helicopter pilot and one that I had dreamed about since ...
